Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Incyte (INCY) trades at $111.64, up 0.25% on the day, with a bearish technical signal but strong fundamental performance. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE, supported by recent earnings beats. Key developments include FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is mixed: strong fundamentals and analyst consensus (52.28% buy rating, $132.43 target) suggest upside, but technical bearishness and reliance on pipeline execution post-2029 pose risks. Earnings growth and pipeline advancements are key catalysts, while competitive pressures and market volatility remain concerns.
Read full analysis

Key Stats

  • Market Cap
    $22.01B
  • Volume
    2,589,484
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $85.96
  • Typical Hold Time
    33 Days
  • Enterprise Value
    $17.52B
  • Div Yield
    -
  • Trading Activity
    -
$111.5
52W Low: $85.96
14 Oct 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $85.96 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

Leonardo DRS wins 10-year NASA SEWP VI contract to supply federal agencies with defense tech through 2036

Leonardo DRS secured a 10-year prime contract under NASA's SEWP VI program, enabling federal agencies to quickly procure its defense products and services until 2036. This contract extends DRS's role as a SEWP prime contractor, supporting key militar...

Market News
37 minutes ago
Na
Bullish
news icon
Leonardo DRS wins 10-year NASA SEWP VI contract to supply federal agencies with defense tech through 2036

Honey Badger Silver reports high-grade polymetallic samples at Yava, reviving interest in northern Canada's VMS deposits.

Honey Badger Silver announced promising assay results from its first exploration program at the Yava Project in Nunavut, revealing high-grade silver, copper, gold, zinc, and lead samples. This marks the first systematic work at Yava in nearly two dec...

Market News
1 hour ago
Mining Stocks News Commentary
Bullish
news icon
Honey Badger Silver reports high-grade polymetallic samples at Yava, reviving interest in northern Canada's VMS deposits.

Brasil DNA Virtual Roadshow connects 187 travel pros with 90+ Brazilian suppliers, boosting tourism ties.

The Brasil DNA Virtual Roadshow held in October 2026 brought together 187 travel professionals from the US and Canada, facilitating 551 connections with over 90 Brazilian tourism suppliers across 54 booths. The event generated 741 leads and featured ...

Market News
1 hour ago
Not Specified
Neutral
Brasil DNA Virtual Roadshow connects 187 travel pros with 90+ Brazilian suppliers, boosting tourism ties.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $22.01B
  • Volume
    2,589,484
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $85.96
  • Typical Hold Time
    33 Days
  • Enterprise Value
    $17.52B
  • Div Yield
    -
  • Trading Activity
    -
$111.5
52W Low: $85.96
14 Oct 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $85.96 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!